Show simple item record

dc.contributor.authorMartinez, J P
dc.contributor.authorSasse, F
dc.contributor.authorBrönstrup, M
dc.contributor.authorDiez, J
dc.contributor.authorMeyerhans, A
dc.date.accessioned2015-02-11T15:58:06Z
dc.date.available2015-02-11T15:58:06Z
dc.date.issued2015-01
dc.identifier.citationAntiviral drug discovery: broad-spectrum drugs from nature. 2015, 32 (1):29-48 Nat Prod Repen
dc.identifier.issn1460-4752
dc.identifier.pmid25315648
dc.identifier.doi10.1039/c4np00085d
dc.identifier.urihttp://hdl.handle.net/10033/344378
dc.description.abstractCovering: up to April 2014. The development of drugs with broad-spectrum antiviral activities is a long pursued goal in drug discovery. It has been shown that blocking co-opted host-factors abrogates the replication of many viruses, yet the development of such host-targeting drugs has been met with scepticism mainly due to toxicity issues and poor translation to in vivo models. With the advent of new and more powerful screening assays and prediction tools, the idea of a drug that can efficiently treat a wide range of viral infections by blocking specific host functions has re-bloomed. Here we critically review the state-of-the-art in broad-spectrum antiviral drug discovery. We discuss putative targets and treatment strategies, with particular focus on natural products as promising starting points for antiviral lead development.
dc.language.isoenen
dc.subject.meshAntiviral Agentsen
dc.subject.meshBiological Productsen
dc.subject.meshDrug Delivery Systemsen
dc.subject.meshDrug Discoveryen
dc.subject.meshHumansen
dc.subject.meshMolecular Structureen
dc.titleAntiviral drug discovery: broad-spectrum drugs from nature.en
dc.typeArticleen
dc.contributor.departmentHelmholtz Centre for infection research (HZI), Inhoffenstr. 7, 38124 Braunschweig, Germany.en
dc.identifier.journalNatural product reportsen
refterms.dateFOA2015-11-15T00:00:00Z
html.description.abstractCovering: up to April 2014. The development of drugs with broad-spectrum antiviral activities is a long pursued goal in drug discovery. It has been shown that blocking co-opted host-factors abrogates the replication of many viruses, yet the development of such host-targeting drugs has been met with scepticism mainly due to toxicity issues and poor translation to in vivo models. With the advent of new and more powerful screening assays and prediction tools, the idea of a drug that can efficiently treat a wide range of viral infections by blocking specific host functions has re-bloomed. Here we critically review the state-of-the-art in broad-spectrum antiviral drug discovery. We discuss putative targets and treatment strategies, with particular focus on natural products as promising starting points for antiviral lead development.


Files in this item

Thumbnail
Name:
Martinez et al_final.pdf
Size:
1.990Mb
Format:
PDF
Description:
corrected proofs

This item appears in the following Collection(s)

Show simple item record